Although the new generation of EGFR-TKIs has been developed, gefitinib is still widely used due to its lower price and being recommended as a first-line agent in patients with newly diagnosed stage IV NSCLC with EGFR-positive mutations by the Chinese Society of Clinical Oncology Guidelines (CSCO) 2020. Here, EGFR is linked to non-small cell lung carcinoma.